[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Bangladesh\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":667},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,130,0,25,[9,40,69,98,122,148,176,203,229,255,287,313,339,376,400,418,437,461,486,504,529,552,583,614,640],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100653258","efficacy-and-safety-of-low-dose-duloxetine-plus-alpha-lipoic-acid-versus-standard-dose-duloxetine-in-painful-diabetic-peripheral-neuropathy-100653258",false,"NCT07785544","Efficacy and Safety of Low-Dose Duloxetine Plus Alpha-Lipoic Acid Versus Standard-Dose Duloxetine in Painful Diabetic Peripheral Neuropathy","Efficacy and Safety of Low-Dose Duloxetine Plus Alpha-Lipoic Acid Versus Standard-Dose Duloxetine in Painful Diabetic Peripheral Neuropathy: An Assessor-Blinded Randomized Controlled Non-Inferiority Trial","Inclusion Criteria:\n\n* Age ≥18 years.\n* Diagnosed case of diabetes mellitus.\n* Diabetic peripheral neuropathy diagnosed clinically according to the Toronto Clinical Neuropathy Score (TCNS) criteria with a TCNS score ≥6, with painful neuropathy confirmed using the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) Pain Scale with a score ≥12.\n* Duration of neuropathic symptoms ≥3 months.\n* Baseline Numerical Rating Scale (NRS) pain score ≥4.\n* Willingness to participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n* Pain attributable to causes other than diabetic peripheral neuropathy, such as peripheral arterial disease (ischaemic pain), osteoarthritis, inflammatory arthritis, phantom limb pain, radiculopathy, or other chronic pain disorders.\n* Known vitamin B12 deficiency, hypothyroidism, chronic alcohol use, hereditary neuropathy, chemotherapy-induced neuropathy, HIV infection, or connective tissue disease.\n* Chronic kidney disease (CKD) stage ≥4.\n* Chronic liver disease or significant hepatic impairment (ALT \\>3 times the upper normal limit).\n* Use of antidepressants, antiepileptic drugs, sedatives, antipsychotic drugs, or opioids within the preceding 4 weeks.\n* Pregnancy or lactation, or women planning pregnancy during the study period.\n* Known hypersensitivity or contraindication to duloxetine or alpha-lipoic acid.\n* Major depressive disorder as assessed by the Patient Health Questionnaire-9 (PHQ-9), cognitive impairment (MMSE \\\u003C24), active malignancy, or any serious medical condition that, in the opinion of the investigator, may interfere with study participation, treatment adherence, or outcome assessment.","ALL","18 Years",{"count":20,"type":21},170,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study will evaluate the efficacy and safety of low-dose duloxetine combined with alpha-lipoic acid compared with standard-dose duloxetine in adults with painful diabetic peripheral neuropathy. In this assessor-blinded, randomized, parallel-arm, non-inferiority trial, participants will be assigned in a 1:1 ratio to receive either duloxetine 30 mg once daily plus alpha-lipoic acid 600 mg once daily or duloxetine 60 mg once daily. The primary outcome will be the change in pain intensity measured by the Numerical Rating Scale from baseline to Week 9. Secondary outcomes will include changes in pain intensity at Week 5, Patient Global Impression of Change at Weeks 5 and 9, the proportion of participants achieving at least a 30% reduction in pain intensity, adverse effects, treatment tolerability and treatment compliance.",[27],"Painful Diabetic Peripheral Neuropathy","NOT_YET_RECRUITING","2026-08-21",{"date":31,"type":32},"2026-08-25","ACTUAL",{"date":31,"type":21},{"date":35,"type":21},"2027-08",{"name":37,"class":38},"Bangladesh Medical University","OTHER",1,{"id":41,"slug":42,"hasResults":12,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":49,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100653282","phase-2-efficacy-and-safety-of-mycophenolate-mofetil-in-refractory-iga-nephropathy-100653282","NCT07785128","Efficacy and Safety of Mycophenolate Mofetil in Refractory IgA Nephropathy","Efficacy and Safety of Mycophenolate Mofetil in Patients With Refractory IgA Nephropathy in Bangladesh: A Phase II Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥18 years Biopsy-proven refractory IgA nephropathy, defined as persistent proteinuria \\>1.0 g\u002Fday despite completion of optimized supportive therapy according to KDIGO recommendations, including corticosteroid and\u002For immunosuppressive therapy and ACE inhibitor and\u002For angiotensin receptor blocker therapy (unless contraindicated) for a minimum of six months eGFR ≥30 mL\u002Fmin\u002F1.73 m² at enrollment\n\nExclusion Criteria:\n\n* Complete or partial remission of IgA nephropathy at enrollment Secondary IgA nephropathy associated with systemic diseases Diabetes mellitus with diabetic kidney disease or any other known non-IgA cause of proteinuria End-stage renal disease requiring dialysis or previous kidney transplantation eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m² at enrollment Active infection requiring systemic antimicrobial therapy Significant hepatic impairment (ALT or AST \\>3 times the upper limit of normal) Pregnancy, planned pregnancy, or breastfeeding Known hypersensitivity or contraindication to MMF",{"count":48,"type":21},104,[50],"PHASE2","This study is testing whether a medicine called mycophenolate mofetil (MMF) works better than the usual treatment for people whose kidney disease, called IgA nephropathy, has not improved with standard care.\n\nIgA nephropathy is a kidney disease that can cause protein to leak into the urine and, over time, can damage the kidneys. Some people with this disease do not get better even after standard treatment. Doctors call this \"refractory\" disease. Right now, there is no proven best treatment for these patients in Bangladesh.\n\nThis study will include 116 adults with kidney disease that has been confirmed by a kidney tissue sample and has not improved with standard treatment. Participants will be split into two equal groups by chance, like a coin flip. One group will take MMF by mouth for 6 months, along with the usual supportive care. The other group will take a steroid medicine called prednisolone, along with the usual supportive care. Both groups will also continue treatments like blood pressure medicines that are already part of standard care for this condition.\n\nResearchers want to find out how many people in each group get better, meaning their urine protein drops to a low level and their kidney function stays stable. They will also look at changes in kidney function and any side effects from the medicines.\n\nThe study will take place at the National Institute of Kidney Diseases and Urology Hospital in Dhaka, Bangladesh, over about one year. Each participant will be followed for 6 months, with check-up visits and blood and urine tests at the start, at 3 months, and at 6 months.",[53],"IgA Nephropathy",[55,56,57,58,59],"Mycophenolate mofetil","IgA nephropathy","Refractory proteinuria","Immunosuppressive therapy","Bangladesh","2026-08-20",{"date":31,"type":32},{"date":63,"type":21},"2026-09-01",{"date":65,"type":21},"2027-08-31",{"name":67,"class":38},"Shaheed Suhrawardy Medical College and Hospital",3,{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100653167","hptc-versus-afsm-in-diabetic-foot-ulcers-100653167","NCT07781917","HPTC Versus AFSM in Diabetic Foot Ulcers","A Multicentric, Randomized, Controlled Clinical Trial Comparing High-Purity Type-I Collagen-Based Skin Substitute Versus Acellular Intact Fish Skin Matrix in the Treatment of Diabetic Foot Ulcers","Inclusion Criteria:\n\n* Subjects must be at least 18 years of age or older.\n* Subjects must have a diagnosis of type 1 or 2 diabetes mellitus.\n* Diabetic foot ulcer located below the malleoli, Wagner Grade 1 or 2 (University of Texas Grade 1-2), without exposed bone.\n* Target ulcer present for a minimum of 4 weeks, with post-debridement area of approximately 5-20 cm².\n* Failure to achieve ≥30% ulcer-area reduction during the run-in period, or an equivalent documented waiver (Section 12.1).\n* Adequate circulation to the affected foot: ankle-brachial index (ABI) between 0.7 and 1.3 (or alternative vascular criteria per protocol).\n* Glycated haemoglobin (HbA1c) ≤ 12%.\n* The subject must consent to using the prescribed off-loading method for the duration of the study.\n* The subject must agree to attend the scheduled study visits required by the protocol.\n* The subject must be willing and able to participate in the informed consent process.\n* Patients must have read and signed the IEC-approved ICF before screening procedures are undertaken.\n\nExclusion Criteria:\n\n* A subject known to have a life expectancy of less than 6 months.\n* If the target ulcer is infected or if there is cellulitis in the surrounding skin.\n* Presence of osteomyelitis or exposed bone, probes to bone or joint capsule on investigator's exam or radiographic evidence; Wagner Grade ≥3.\n* A subject that has an infection in the target ulcer that requires systemic antibiotic therapy.\n* A subject receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy.\n* Topical application of steroids to the ulcer surface within one month of initial screening.\n* A subject with a previous partial amputation on the affected foot, if the resulting deformity impedes proper offloading of the target ulcer.\n* A subject with glycated haemoglobin (HbA1c) greater than 12% at or within 3 months of the initial screening visit.\n* A subject with an acute Charcot foot, or an inactive Charcot foot that impedes proper offloading of the target ulcer.\n* Women who are pregnant or considering becoming pregnant within the next 6 months.\n* A subject with end-stage renal disease requiring dialysis; active malignancy.\n* A subject who participated in a clinical trial involving treatment with an investigational product within the previous 30 days.\n* A subject who, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments.\n* A subject treated with hyperbaric oxygen therapy or a cellular and\u002For tissue product (CTP) in the 30 days prior to the initial screening visit.\n* Known hypersensitivity to HPTC or its components; known fish allergy\u002Fhypersensitivity for participants who would be allocated to AFSM.","75 Years",{"count":78,"type":21},120,[24],"This is a randomized controlled clinical investigation in patients suffering from diabetic foot ulcers at multiple centres in India and Bangladesh. The study compares patient outcomes using standard wound care with a High Purity Type-I Collagen-Based Skin Substitute against standard wound care with an Acellular Intact Fish Skin Matrix.",[82],"Diabetic Foot Ulcer (DFU)",[84,85,86,87,88],"Diabetic Foot Ulcer;","High Purity Type-I Collagen-Based Skin Substitute;","Acellular Intact Fish Skin Matrix;","Randomized Controlled Clinical Trial;","Multicentric Study;",{"date":90,"type":32},"2026-08-24",{"date":92,"type":21},"2026-08",{"date":94,"type":21},"2027-03",{"name":96,"class":38},"Adichunchanagiri Institute of Medical Sciences, B G Nagara",4,{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":115,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":39},"100628380","the-impact-of-low-sodium-salt-substitute-use-on-serum-potassium-levels-among-patients-with-hypertension-100628380","NCT07460882","The Impact of Low Sodium Salt Substitute Use on Serum Potassium Levels Among Patients With Hypertension","Inclusion Criteria:\n\n* Adults ≥18 years with clinically diagnosed hypertension treated with medication \\[on a stable dose at least for 2 months\\]\n* Have a phone for contact\n\nExclusion Criteria:\n\n* Those with baseline K ≥5.0 or K \\\u003C3.0 mmol\u002FL\n* Advanced kidney disease (eGFR \\\u003C45 ml\u002Fmin\u002F1.73m2).\n* Those on potassium sparing diuretics (e.g., spironolactone)\n* Other medical conditions determined by physicians (e.g., heart failure treated with medication; life expectancy less than 12 months)\n* Dine out for dinner more than 3 times a week",{"count":105,"type":21},607,[24],"The goal of this pre-post study is to assess the risk of hyperkalemia in adults with hypertension on medication in Bangladesh. The main questions it aims to answer are:\n\nIs the risk of hyperkalemia after the initiation of Low Sodium Salt Substitute (LSSS) in people on antihypertensive medication (especially RASi) large enough to be concerned about its broad use in this population?\n\nDoes initiation of LSSS correct hypokalemia in people on antihypertensive medication (especially RASi) with low serum potassium levels?\n\nParticipants will be asked to reduce overall salt intake and to use LSSS on every occasion where regular salt would normally be used, including as cooking salt.",[109],"Hypertension",[109,111,112,113],"Low sodium salt substitute","Cardiovascular disease","RASi","RECRUITING",{"date":29,"type":32},{"date":117,"type":32},"2026-08-08",{"date":119,"type":21},"2027-09-30",{"name":121,"class":38},"Johns Hopkins University",{"id":123,"slug":124,"hasResults":12,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":12,"sex":17,"minAge":129,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":39},"100627633","phase-2-comparative-efficacy-of-antibiotics-for-small-intestine-bacterial-overgrowth-in-bangladeshi-children-100627633","NCT07451171","Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children","A Phase II Trial to Prevent Linear Growth Stunting and Malnutrition in Impoverished Children From a Low-Income Country by Treating Small Intestine Bacterial Overgrowth","Inclusion Criteria:\n\n* Positive glucose hydrogen breath test (GHBT)\n* Weight-for-age Z score \\> -1\n* Length-for-age Z score \\> -1\n\nExclusion Criteria:\n\n* Presence of known chronic or congenital illness, including developmental delay\n* Presence of acute gastrointestinal illness in the preceding 14 days\n* Antibiotic use in the preceding 14 days\n* Previous adverse reaction to any of the three study medications or other drugs in the same antibiotic classes\n* Sibling previously enrolled in this study","1 Year","2 Years",{"count":132,"type":21},60,[50],"The purpose of this Phase IIa study is to identify the most effective antibiotic regimen to treat small intestine bacterial overgrowth (SIBO) in impoverished Bangladeshi children.",[136],"Small Intestine Bacterial Overgrowth",[138],"environmental enteric dysfunction","2026-08-14",{"date":141,"type":32},"2026-08-18",{"date":143,"type":32},"2026-04-18",{"date":145,"type":21},"2026-12-02",{"name":147,"class":38},"University of Virginia",{"id":149,"slug":150,"hasResults":12,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":158,"briefSummary":159,"conditions":160,"keywords":165,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":173,"leadSponsor":175,"locationsCount":39},"100650591","zepu-ai9-exoskeleton-rehabilitation-robot-100650591","NCT07750808","ZEPU AI9 Exoskeleton Rehabilitation Robot","Feasibility, Safety and Efficacy of ZEPU AI9 Lower Limb Exoskeleton Rehabilitation Robot in Patients With Lower Limb Motor Dysfunction","Inclusion Criteria:\n\n* Age ≥ 18 and ≤ 60 years.\n* Lower-limb motor dysfunction from one of the following: (a) stroke (onset 2-24 months), (b) incomplete spinal-cord injury (neurological level T12 and below, ASIA C or D), (c) orthopedic surgery (e.g., knee\u002Fhip replacement) with persistent gait impairment \\> 3months post-surgery.\n* Able to provide informed consent and understand instructions.\n* Weight ≤ 100 kg (as per device spec) and height within device adjustable range (manufacturer spec).\n* Medically stable and cleared by physician for exoskeleton use (no active infection, uncontrolled cardiac\u002Frespiratory disease, severe osteoporosis, uncontrolled epilepsy, untreated DVT) with necessary investigations.\n\nExclusion Criteria:\n\n* Complete spinal cord injury with inability to bear any weight.\n* Severe cognitive impairment (e.g., MMSE \\\u003C 24) preventing safe participation.\n* Severe spasticity (Modified Ashworth Scale \\> 3) in lower limbs.\n* Unstable fractures, severe hip\u002Fknee contractures (\\> 30° fixed flexion), severe osteoarthritis requiring imminent surgery.\n* Uncontrolled cardiac arrhythmia, pacemaker incompatibility, or implanted electronic device incompatible with robot sensors.\n* Pregnancy.","60 Years",{"count":157,"type":21},36,[24],"The goal of this clinical trial is to learn whether the ZEPU AI9 lower limb exoskeleton robot is feasible, safe, and effective for people with walking difficulty caused by stroke, incomplete spinal cord injury, or orthopedic surgery. The main questions it aims to answer are:\n\nIs exoskeleton-assisted gait training well tolerated, and how often do device-related problems (such as falls, pain, or skin injury) occur? Does adding exoskeleton training to usual rehabilitation improve walking distance, walking speed, balance, muscle strength, and joint movement compared with usual rehabilitation alone? Is it practical to add this robotic training into the rehabilitation program at Bangladesh Medical University?\n\nResearchers will compare a group receiving exoskeleton-assisted gait training plus standard rehabilitation to a group receiving standard rehabilitation alone, to see whether the exoskeleton adds benefit.\n\nParticipants will:\n\nBe randomly assigned to either the exoskeleton group or the standard-care group If assigned to the exoskeleton group, attend 45-minute training sessions 3 times a week for 12 weeks, supervised by physical therapists with safety harness support Both groups will continue their usual rehabilitation therapy throughout the study Undergo walking, balance, strength, and quality-of-life assessments at the start of the study and every 2 weeks for 12 weeks Be monitored for any side effects or safety concerns during and after each session",[161,162,163,164],"Stroke","Gait Disorders, Neurologic","Spinal Cord Injuries, Incomplete","Postoperative Complication",[166,167,168],"Lower limb exoskeleton","Robotic Rehabilitation","Neurorehabilitation","2026-08-06",{"date":171,"type":32},"2026-08-10",{"date":92,"type":21},{"date":174,"type":21},"2026-12",{"name":37,"class":38},{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":155,"enrollmentInfo":183,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":185,"conditions":186,"keywords":191,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":199,"completionDateStruct":200,"leadSponsor":202,"locationsCount":39},"100650652","zepu-ai-series-limb-feedback-robot-training-study-zepuaisrct-100650652","NCT07749625","ZEPU-AI Series Limb Feedback Robot Training Study (ZEPUAISRCT)","Feasibility, Safety and Efficacy of ZEPU-AI2, AI4, AI6 Plus and AI7A Robotic Rehabilitation Systems in Patients With Upper and Lower Limb Motor Dysfunction","Inclusion Criteria:\n\n* Presence of upper-limb motor dysfunction, with or without concurrent lower-limb impairment, due to one of the following conditions: (a) Stroke, with onset between 2 and 24 months prior to enrollment; (b) Incomplete spinal cord injury (ASIA Scale B, C, or D); (c) Traumatic brain injury; or (d) Orthopedic disorders affecting upper and\u002For lower limb motor function\n* Age between 18 and 60 years\n* Ability to understand study procedures and follow instructions, and to provide written informed consent (or assent with guardian consent where applicable)\n* Body weight and limb anthropometry compatible with ZEPU-AI2, AI4, AI6 Plus, and AI7A systems, as per manufacturer specifications\n* Medically stable and cleared by a physician for robotic rehabilitation, with no active infection, uncontrolled cardiac or respiratory disease, severe osteoporosis, uncontrolled epilepsy, or untreated deep vein thrombosis\n\nExclusion Criteria:\n\n* Complete spinal cord injury or profound motor paralysis preventing safe interaction with robotic devices\n* Severe cognitive impairment, defined as a Mini-Mental State Examination (MMSE) score \\\u003C 24, that would compromise safe participation\n* Severe spasticity of the upper limb, defined as a Modified Ashworth Scale score \\> 3\n* Unstable fractures, severe fixed joint contractures of the shoulder, elbow, wrist, or hand (e.g., \\> 30°), or severe pain limiting safe robotic training\n* Uncontrolled cardiac arrhythmia, presence of a pacemaker, or other implanted electronic medical devices incompatible with robotic sensors\n* Pregnancy",{"count":157,"type":21},[24],"The goal of this clinical trial is to learn whether robotic rehabilitation devices (ZEPU-AI2, AI4, AI6 Plus, and AI7A) are feasible, safe, and effective for adults with upper or lower limb motor problems. These problems can result from stroke, incomplete spinal cord injury, traumatic brain injury, or orthopedic surgery. The main questions it aims to answer are:\n\nIs robotic rehabilitation training safe and practical to deliver alongside conventional therapy? Does adding robotic-assisted therapy improve motor function, balance, gait, and independence in daily activities compared to conventional rehabilitation alone? What side effects or device-related problems, if any, occur during robotic training?\n\nThe Investigators will compare a robotic-augmented rehabilitation group to a control group receiving conventional rehabilitation alone, to see if adding robotic therapy leads to better recovery.\n\nParticipants will:\n\nReceive robotic-assisted therapy sessions three times a week for 12 weeks, each lasting about 45 minutes (robotic group), or continue with conventional rehabilitation alone (control group) Undergo assessments of movement, balance, walking ability, and daily function before and after the study period Be monitored for any side effects or complications related to the device or training",[161,187,188,189,190],"Spinal Cord Injuries","Brain Injuries, Traumatic","Movement Disorder, Upper Extremity","Movement Disorder, Lower Extremity",[167,192,193,194,195,168,196],"ZEPU-AI2","ZEPU-AI4","ZEPU-AI6 Plus","ZEPU-AI7A","Musculoskeletal Rehabilitation","2026-08-04",{"date":169,"type":32},{"date":92,"type":21},{"date":201,"type":21},"2026-11",{"name":37,"class":38},{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":155,"enrollmentInfo":210,"targetDuration":4,"studyType":22,"phases":211,"briefSummary":212,"conditions":213,"keywords":218,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":225,"startDateStruct":226,"completionDateStruct":227,"leadSponsor":228,"locationsCount":39},"100650564","zepu-2000-limb-rehabilitation-trainer-study-zepu2000rct-100650564","NCT07749612","ZEPU-2000 Limb Rehabilitation Trainer Study (ZEPU2000RCT)","Feasibility, Safety and Efficacy of ZEPU-2000A, ZEPU-2000D and ZEPU-2000E Upper and Lower Limb Active and Passive Rehabilitation Trainer Systems in Patients With Upper and Lower Limb Motor Dysfunction","Inclusion Criteria:\n\n* Presence of upper-limb motor dysfunction, with or without concurrent lower-limb impairment, due to one of the following: stroke with onset between 2 and 24 months prior to enrolment; incomplete spinal cord injury (neurological level C5 and below), classified as ASIA Impairment Scale C or D; traumatic brain injury with persistent upper-limb functional limitation; or orthopedic\u002Fpost-surgical conditions involving the shoulder, elbow, wrist, or hand with persistent functional impairment for more than 3 months\n* Age between 18 and 60 years\n* Ability to understand study procedures and follow instructions, and to provide written informed consent (or assent with guardian consent where applicable)\n* Body weight and limb anthropometry compatible with ZEPU-2000A, ZEPU-2000D, and ZEPU-2000E systems, per manufacturer specifications\n* Medically stable and cleared by a physician for robotic rehabilitation, with no active infection, uncontrolled cardiac or respiratory disease, severe osteoporosis, uncontrolled epilepsy, or untreated deep vein thrombosis\n\nExclusion Criteria:\n\n* Complete spinal cord injury or profound motor paralysis preventing safe interaction with robotic devices\n* Severe cognitive impairment, defined as a Mini-Mental State Examination (MMSE) score less than 24, that would compromise safe participation Severe spasticity of the upper limb, defined as a Modified Ashworth Scale score greater than 3\n* Unstable fractures, severe fixed joint contractures of the shoulder, elbow, wrist, or hand (e.g., greater than 30 degrees), or severe pain limiting safe robotic training\n* Uncontrolled cardiac arrhythmia, or presence of a pacemaker or other implanted electronic medical device incompatible with robotic sensors\n* Pregnancy",{"count":157,"type":21},[24],"The goal of this clinical trial is to learn whether the ZEPU-2000A, ZEPU-2000D and ZEPU-2000E robotic rehabilitation trainers help people with weakness or movement problems in their arms and legs. These devices are used to guide repeated arm and leg movements as part of rehabilitation therapy. The study will also look at whether the devices are safe to use.\n\nThe main questions it aims to answer are:\n\nIs training with the ZEPU-2000 devices safe, and how well do patients tolerate and stick with the training sessions? Does adding robotic training to usual rehabilitation improve muscle strength, joint movement, balance, walking, and daily function more than usual rehabilitation alone?\n\nResearchers will compare a group receiving robotic-assisted rehabilitation plus usual care to a group receiving usual rehabilitation care alone, to see whether the robotic devices provide added benefit.\n\nParticipants will:\n\nBe adults aged 18-60 with arm and\u002For leg movement problems caused by stroke, incomplete spinal cord injury, traumatic brain injury, or an orthopedic condition Attend training sessions 3 times a week for 12 weeks (about 36 sessions total), each lasting approximately 45 minutes Undergo assessments of strength, movement, balance, and daily function at the start of the study and every 2 weeks throughout the 12-week period Be monitored for any side effects or safety concerns, such as skin irritation, falls, or discomfort, at every session",[161,214,215,216,217],"Incomplete Spinal Cord Injury (SCI)","Traumatic Brain Injury","Upper Extremity Motor Dysfunction","Lower Extremity Motor Dysfunction",[219,220,221,222,223,168,224],"Robotic rehabilitation","ZEPU-2000A","ZEPU-2000D","ZEPU-2000E","Active and passive rehabilitation","Musculoskeletal rehabilitation",{"date":169,"type":32},{"date":92,"type":21},{"date":174,"type":21},{"name":37,"class":38},{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":236,"sex":17,"minAge":237,"maxAge":238,"enrollmentInfo":239,"targetDuration":4,"studyType":22,"phases":241,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":39},"100650679","nvtia-ergothioneine-for-healthy-aging-and-skin-health-100650679","NCT07750002","NVTIA® Ergothioneine for Healthy Aging and Skin Health","A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Effects of NVTIA® Ergothioneine Supplementation on Healthy Aging Biomarkers and Skin Health in Healthy Adults","Inclusion Criteria:\n\n* Participants must meet all of the following criteria:\n\n  * Male or female adults aged 35 to 55 years.\n  * Generally healthy as determined by medical history, physical examination, and screening assessments.\n  * Body Mass Index (BMI) between 18.5 and 29.9 kg\u002Fm².\n  * Willing and able to provide written informed consent.\n  * Willing to maintain their usual diet, physical activity, and lifestyle throughout the study period.\n  * Willing to avoid the use of other antioxidant, anti-aging, or nutritional supplements during the study period unless approved by the investigator.\n  * Able and willing to comply with all study procedures and scheduled visits.\n\nExclusion Criteria:\n\n* Participants meeting any of the following criteria will be excluded:\n\n  * History of clinically significant cardiovascular, hepatic, renal, gastrointestinal, endocrine, neurological, or psychiatric disease.\n  * Current diagnosis of diabetes mellitus requiring medication.\n  * Active inflammatory or autoimmune disease.\n  * History of malignant disease within the previous five years.\n  * Pregnancy, breastfeeding, or planning pregnancy during the study period.\n  * Known allergy or hypersensitivity to ergothioneine or any ingredient of the study product.\n  * Use of antioxidant supplements, anti-aging supplements, or investigational products within 30 days before enrollment.\n  * Current smoker or history of heavy alcohol consumption.\n  * Participation in another clinical trial within the previous 30 days.\n  * Any medical condition or laboratory abnormality that, in the opinion of the investigator, may interfere with study participation or interpretation of study results.",true,"35 Years","55 Years",{"count":240,"type":21},50,[24],"This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effects of NVTIA® Ergothioneine, a branded ergothioneine ingredient, on healthy aging biomarkers and skin health in healthy adults aged 40 to 65 years. Participants will receive either NVTIA® Ergothioneine or a matching placebo once daily for 12 weeks.\n\nThe primary objective of this study is to evaluate the effects of NVTIA® Ergothioneine supplementation on biomarkers associated with oxidative stress and healthy aging. Secondary objectives include assessment of skin elasticity, skin hydration, inflammatory biomarkers, and overall safety. The findings of this study are expected to provide clinical evidence supporting the role of NVTIA® Ergothioneine in promoting healthy aging and maintaining skin health.",[244,245,246],"Healthy Aging","Skin Aging","Oxidative Stress","2026-08-03",{"date":169,"type":32},{"date":250,"type":21},"2026-08-15",{"date":252,"type":21},"2027-04-08",{"name":254,"class":38},"EUROPEAN LIFE SCIENCE RESEARCH ASSOCIATION",{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":236,"sex":263,"minAge":264,"maxAge":18,"enrollmentInfo":265,"targetDuration":4,"studyType":22,"phases":267,"briefSummary":269,"conditions":270,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":281,"startDateStruct":282,"completionDateStruct":283,"leadSponsor":285,"locationsCount":39},"100646025","phase-3-micronutrient-enhancement-for-development-and-health-in-adolescents---the-medha-study-100646025","NCT07695883","Micronutrient Enhancement for Development and Health in Adolescents - The MEDHA Study","Micronutrient Enhancement for Development and Health in Adolescents","MEDHA","Inclusion Criteria:\n\n* Unmarried 10-18 year old females\n* living in their parental home in the study area\n\nExclusion Criteria:\n\n* Married females under 18 years old;\n* those with a history or diagnosis of chronic or congenital heart disease, chronic kidney or lung disease, cancer, and epilepsy","FEMALE","10 Years",{"count":266,"type":21},3000,[268],"PHASE3","MEDHA is a randomized controlled trial among 10-18 year old girls to examine the use-case of the United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) multiple micronutrient supplement (MMS) formulation and to test an enhanced regimen (MMS+) with additional nutrients, vs. weekly iron-folic acid as standard of care on outcomes of neurodevelopment, linear growth, biochemical status, bone health, and other functional and health outcomes. This study is an individually randomized, open-label, three-arm trial of 3,000 participants supplemented for 12 months to assess the efficacy and safety of nutrient supplementation. Results of the study will inform the design of nutritional interventions and policy for this age group. In the context of the trial, the investigators will also do in-depth clinical and health assessments and collect biospecimens for a bio-archive for future deep-phenotyping of this population. This study will be conducted at the Johns Hopkins Bangladesh JiVitA field site in rural Gaibandha District of Bangladesh.",[271,272,273,274,275,276,277,278,279,280],"Neurodevelopment Outcome","Linear Growth","Micronutrient Status","Bone Mineral Density","Underweight","Stunting","Body Composition","Blood Pressure","HRQOL (Health Related Quality Of Life)","Waist-to-height Ratio",{"date":169,"type":32},{"date":63,"type":21},{"date":284,"type":21},"2028-06-30",{"name":286,"class":38},"Johns Hopkins Bloomberg School of Public Health",{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":236,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":297,"phases":4,"briefSummary":298,"conditions":299,"keywords":4,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":306,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":39},"100643532","gut-leakage-in-dengue-100643532","NCT07602920","Gut Leakage' in Dengue","Gut Leakage and Sonographic Abdominal Changes in Hospitalized Dengue Patients: an Observational Study","GLiD","Inclusion Criteria:\n\nDengue participants\n\n* Participant\u002F legally authorised representative willing and able to give informed consent for participation in the study.\n* Male or Female, adults ≥18 years\n* Diagnosed as a case of Dengue on the basis of clinical features and positive NS1 antigen and\u002For IgM dengue antibody\n* Hospitalized in medicine or dengue ward in Chittagong Medical College Hospital.\n* Enrolled within 24 hours of hospitalization.\n\nHealthy participants\n\n* Participant\u002F legally authorised representative willing and able to give informed consent for participation in the study.\n* Male or Female, adults ≥18 years\n* Clinically healthy with no acute or chronic illness\n* Attendant of a dengue patient (not a patient)\n\nExclusion Criteria:\n\nDengue participants\n\n* Unable to provide consent or participate in follow-up procedures\n* Known chronic gastrointestinal (GI) disease affecting intestinal permeability (IBD, celiac disease), chronic liver disease, active chronic diarrhoea, short bowel loop syndrome, recent (\\\u003C3 months) major GI surgery.\n* Immunosuppression (for example chemotherapy, high-dose steroids), advanced chronic kidney disease, decompensated heart failure.\n* Drugs that can alter the level of biomarkers in blood like metformin, statin, probiotics, steroid within last 48 hours of hospitalization.\n* Pregnancy\n\nHealthy participants\n\n* Unable to provide consent\n* Known chronic gastrointestinal (GI) disease affecting intestinal permeability (IBD, celiac disease), chronic liver disease, active chronic diarrhoea, short bowel loop syndrome, recent (\\\u003C3 months) major GI surgery.\n* Immunosuppression (for example chemotherapy, high-dose steroids), advanced chronic kidney disease, decompensated heart failure.\n* Drugs that can alter the level of biomarkers in blood like metformin, statin, probiotics, steroid within last 48 hours of hospitalization.\n* Pregnancy\n* History of current or recent dengue or other arbo viral infection",{"count":296,"type":21},190,"OBSERVATIONAL","Dengue infections are imposing an increasing global burden of disease, particularly in tropical countries such as Bangladesh. The World Health Organization (WHO) has identified Dengue virus as a priority pathogen for the development of medical counter measures because of the high risk of it causing a Public Health Emergency of Intenational Concern (PHEIC). Warning signs for severe dengue, associated with mortality, include gastrointestinal features including abdominal pain, vomiting, and diarrhoea. Multiple alterations may occur in in the gastrointestinal tract that could lead to damaging of the gastrointestinal wall and gut leakage, the translocation of gut metabolites into the bloodstream. Study team hypothesize that gut leakage initiates inflammatory processes underlying the further development of severe dengue, including features associated with plasma leakage.\n\nThis study aims to investigate intestinal barrier dysfunction (gut leakage) in dengue infection by detecting the translocation of gut-derived bacteria and their products (Lipopolysaccharides, LPS binding protein, sCD14, I-Fatty Acid Binding Protein) into the bloodstream. Study team will recruit hospitalized adult dengue patients (18 years and older) presenting with warning signs or severe disease in a tertiary care public hospital at Chattogram, Bangladesh. Circulating biomarkers indicative of gut permeability and microbial translocation will be measured to assess their presence and association with disease severity.\n\nAbdominal ultrasonography will be performed to characterize gastrointestinal alterations and determine their correlation with biochemical markers of gut leakage and clinical severity. In addition, study team will analyze the gut bacteriome from stool\u002F rectal swab of these patients to explore whether dengue infection induces compositional changes in intestinal microbiota and whether such alterations are linked to gut leakage or disease progression.",[300,301,302,303,304,305],"Dengue","Dengue Hemorrhagic Fever","Intestinal Disease","Ascites","Dengue With Warning Signs","Gut Microbiome",{"date":169,"type":32},{"date":308,"type":32},"2026-08-01",{"date":310,"type":21},"2028-01-31",{"name":312,"class":38},"University of Oxford",{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":236,"sex":17,"minAge":321,"maxAge":155,"enrollmentInfo":322,"targetDuration":4,"studyType":22,"phases":324,"briefSummary":326,"conditions":327,"keywords":331,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":333,"startDateStruct":334,"completionDateStruct":335,"leadSponsor":337,"locationsCount":338},"100607908","phase-4-r21mm-dosing-presentations-and-preservatives-100607908","NCT07194668","R21\u002FMM Dosing, Presentations, and Preservatives","Immunogenicity of a Fractional Adult Dose of the Malaria Vaccine R21\u002FMatrix-M - A Noninferiority Trial","VAC100","Inclusion Criteria:\n\n* Residence in a study village for the study period, i.e. 12 months.\n* Age 14 years to 60 years.\n* Written informed consent\u002Fassent provided by participants (or a parent\u002Fguardian in case the participant is under 18 years old).\n\nExclusion Criteria:\n\n* Pregnancy, plan to get pregnant within one month of vaccination, or breastfeeding.\n* Acute illness requiring intervention.\n* A history of an adverse reaction to study vaccine.\n* Prior receipt of any other malaria vaccine.\n* Enrolment in another intervention trial in the last month.\n* Planned enrolment in another intervention trial in the coming 12 months.\n* Regular use of Immunomodulating drugs e.g, Steroid, Methotrexate, Immunotherapy etc. in the past month and\u002For planned for the coming 12 months.","14 Years",{"count":323,"type":21},375,[325],"PHASE4","This is a single blind randomised controlled trial (Phase 3 trial). This study aims to assess whether a half-dose of the R21\u002FMatrix-M malaria vaccine is as effective as the full dose in children and adults. The results will help optimize vaccine usage and improve malaria prevention strategies.\n\nAll participants will receive the same number of injections and will be randomly assigned to receive one of the followings:\n\n* Group 1: Adults and adolescents receiving the standard adult vaccine dose: 10μg R21\u002F50μg Matrix-M (n=125).\n* Group 2: Adults and adolescents receiving a half of the standard adult vaccine dose: 5μg R21\u002F50μg Matrix-M: 10 dose vials with adaptor Preservative Free (n=125)\n* Group 3: Adults and adolescents receiving a half of the standard adult vaccine dose: 5μg R21\u002F50μg Matrix-M: 10 dose vials with 2PE Preservative (n=125)\n\nClinical procedure for participants:\n\n* Standardized symptom questionnaire\n* Physical examination:\n\nWeight, height, pulse, blood pressure, respiratory rate, tympanic temperature. Spleen and liver size will be recorded if palpable. Pregnancy test (for female of child bearing potential)\n\n* Venous blood collection (Pre-vaccination) 3mL\n* Vaccination",[328,329,330],"Plasmodium Falciparum Malaria","Malaria","Vaccine Reaction",[328,332],"Malaria Vaccine",{"date":197,"type":32},{"date":250,"type":21},{"date":336,"type":21},"2026-12-31",{"name":312,"class":38},2,{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":346,"targetDuration":4,"studyType":22,"phases":348,"briefSummary":349,"conditions":350,"keywords":355,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":372,"leadSponsor":374,"locationsCount":39},"100650370","just-in-time-support-for-smoking-vaping-and-eating-urges-during-high-stress-moments-among-gender-and-sexual-minority-adults-in-dhaka-100650370","NCT07746492","Just-in-Time Support for Smoking, Vaping, and Eating Urges During High-Stress Moments Among Gender and Sexual Minority Adults in Dhaka","A Digital Real-Time Support for Stress-Induced Smoking and Unhealthy Eating Among Gender and Sexual Minorities in Dhaka","Inclusion Criteria:\n\n* Age 18 years or older\n* Self-identifies as a gender and\u002For sexual minority person\n* Resides in Dhaka at enrolment and expects to remain in Dhaka throughout the 24-day assessment period\n* Reports at least one qualifying behaviour on average at least 3 days per week during the past month: (a) smoking or vaping, or (b) eating primarily in response to stress, anxiety, or emotional distress\n* Owns a personal Android or iOS smartphone compatible with the study platform that is used solely by the participant and is not shared with others\n* Able to read, understand, and respond to simple Bangla text\n* Able to operate the study app independently after a structured onboarding session\n* Willing to complete five scheduled app-based momentary assessments per day for 24 days and additional brief follow-up assessments after randomized decision points\n* Provides written informed consent\n\nExclusion Criteria:\n\n* Currently participating in another behavioural or pharmacological intervention study targeting smoking, vaping, or eating behaviour\n* Has a severe or unstable psychiatric condition that, based on screening and review by the study clinician, would make participation in the repeated daily assessment protocol unsafe\n* Is unable to operate the study app independently after structured onboarding",{"count":347,"type":21},115,[24],"Gender and sexual minority adults in Bangladesh experience high levels of stigma-related stress. Acute stress can trigger strong, affect-driven urges to smoke, vape, or engage in stress-attributed eating. These urges can rise and fall within minutes to hours, operating outside the reach of conventional clinic-based interventions delivered days or weeks later.\n\nThis pilot micro-randomized trial (MRT) evaluates whether delivering a brief, culturally adapted support message via smartphone during moments of high self-reported stress reduces the intensity of the urge for the participant's pre-specified target behaviour, relative to no message. Over a 24-day period, 115 participants will be scheduled for up to 5 ecological momentary assessments (EMA) per day. Whenever a participant reports an acute stress level of 5 or higher (0 to 10 scale) and satisfies pre-specified privacy, safety, behavioural, and spacing criteria, the app randomizes with probability 0.5 to deliver either a brief support message or no message. By contributing multiple randomized decision points over time, each participant serves as their own micro-control.\n\nThe primary outcome is the intensity of the urge for the participant's pre-specified target behaviour, measured 45 to 60 minutes after randomization. An exploratory urge assessment is also collected 10 minutes after randomization; comparing the two time points will help establish whether the support message's effect is immediate, delayed, or both, and will inform the choice of follow-up window for a future, fully powered trial. Prior to trial launch, all EMA items, message content, notification logic, and digital safety protocols will be developed and tested with community members, reviewed by a Community Advisory Board, and locked.\n\nAs a pilot optimization trial, its objectives are to estimate the short-term causal effect of the prompt, to identify the contexts in which that effect is larger or smaller, and to establish whether momentary assessment and just-in-time intervention research can be delivered safely, privately, and acceptably in this high-stigma setting. The study does not evaluate long-term behavioural maintenance and does not claim to address the underlying structural stigma and discrimination that produce minority stress.",[351,352,353,354],"Tobacco Use","Electronic Cigarette Use","Emotional Eating","Stress, Psychological",[356,357,358,359,360,361,362,363,364,365,59,366,367],"micro-randomized trial","just-in-time adaptive intervention","ecological momentary assessment","mHealth","digital health","minority stress","smoking","vaping","stress-attributed eating","urge","gender and sexual minority","pilot optimization trial","2026-07-30",{"date":370,"type":32},"2026-08-05",{"date":63,"type":21},{"date":373,"type":21},"2027-02-06",{"name":375,"class":38},"International Centre for Diarrhoeal Disease Research, Bangladesh",{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":155,"enrollmentInfo":383,"targetDuration":4,"studyType":22,"phases":384,"briefSummary":385,"conditions":386,"keywords":390,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":399,"locationsCount":39},"100649757","zepu-sgi1plus-hand-training-study-zepusgi1rct-100649757","NCT07739264","ZEPU-SGI1PLUS Hand Training Study (ZEPUSGI1RCT)","Feasibility, Safety and Efficacy of ZEPU-SGI1PLUS Hand Functional Comprehensive Training Systems in Patients With Upper Limb Motor Dysfunction","Inclusion Criteria:\n\n* Presence of upper-limb motor dysfunction, with or without concurrent lower-limb impairment, due to one of the following conditions: (a) stroke, with onset between 2 and 24 months prior to enrollment; (b) incomplete spinal cord injury (neurological level C5 and below), classified as ASIA Impairment Scale C or D; (c) traumatic brain injury with persistent upper-limb functional limitation; or (d) orthopedic or post-surgical conditions involving the shoulder, elbow, wrist, or hand with persistent functional impairment for \\> 3 months\n* Age between 18 and 60 years, inclusive\n* Ability to understand study procedures and follow instructions, and to provide written informed consent (or assent with guardian consent where applicable)\n* Body weight and limb anthropometry compatible with the ZEPU-SG1PLUS Hand Functional Comprehensive Training System per manufacturer specifications\n* Medically stable and cleared by a physician for robotic rehabilitation, with no active infection, uncontrolled cardiac or respiratory disease, severe osteoporosis, uncontrolled epilepsy, or untreated deep vein thrombosis\n\nExclusion Criteria:\n\n* Complete spinal cord injury or profound motor paralysis preventing safe interaction with robotic devices\n* Severe cognitive impairment, defined as a Mini-Mental State Examination (MMSE) score \\\u003C 24, that would compromise safe participation\n* Severe spasticity of the upper limb, defined as a Modified Ashworth Scale score \\> 3\n* Unstable fractures, severe fixed joint contractures of the shoulder, elbow, wrist, or hand (e.g., \\> 30°), or severe pain limiting safe robotic training\n* Uncontrolled cardiac arrhythmia, presence of a pacemaker, or other implanted electronic medical device incompatible with robotic sensors\n* Pregnancy",{"count":157,"type":21},[24],"The goal of this pilot randomized controlled trial is to learn whether the ZEPU-SG1PLUS Hand Functional Comprehensive Training System - a robotic device used alongside standard rehabilitation - is safe, feasible, and helpful for people with upper limb (arm\u002Fhand) motor problems caused by stroke, incomplete spinal cord injury, traumatic brain injury, or orthopedic conditions.\n\nThe main questions it aims to answer are:\n\nIs robotic-assisted hand training well tolerated by patients, and can it be safely added to standard rehabilitation, with acceptable rates of device-related side effects? Does adding robotic hand training to standard rehabilitation improve arm and hand strength, range of motion, and functional ability compared with standard rehabilitation alone? Is it practical to fit this type of robotic training into everyday rehabilitation services at Bangladesh Medical University?\n\nResearchers will compare a robotic-augmented rehabilitation group to a standard-care (control) group to see whether adding robotic hand training works better than usual rehabilitation alone.\n\nParticipants will:\n\nBe randomly assigned to one of two groups: one receiving standard rehabilitation plus robotic hand training with the ZEPU-SG1PLUS device, and one receiving standard rehabilitation alone If assigned to the robotic training group, attend three training sessions per week for 12 weeks, each lasting about 30-45 minutes, at the Robotic Rehabilitation Centre, BMU Undergo assessments at the start of the study and at two-week intervals during the 12-week program and follow-up period, including tests of muscle strength, joint movement, hand function, and daily activity ability Be monitored throughout for any side effects or safety concerns related to the training",[387,161,388,215,389],"Upper Limb Motor Dysfunction","Incomplete Spinal Cord Injury","Upper Limb Orthopedic Trauma",[167,391,392,168,196],"ZEPU-SG1PLUS","Hand Function Training","2026-07-29",{"date":395,"type":32},"2026-07-31",{"date":397,"type":21},"2026-07",{"date":201,"type":21},{"name":37,"class":38},{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":155,"enrollmentInfo":407,"targetDuration":4,"studyType":22,"phases":408,"briefSummary":409,"conditions":410,"keywords":412,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":414,"startDateStruct":415,"completionDateStruct":416,"leadSponsor":417,"locationsCount":39},"100649645","zepu-ai5-strength-training-study-zepuai5rct-100649645","NCT07735702","ZEPU-AI5 Strength Training Study (ZEPUAI5RCT)","Safety, Feasibility and Efficacy of ZEPU AI5 Lower Limb Muscle Strength Training and Evaluation Robot","Inclusion Criteria:\n\n* Lower-limb motor dysfunction due to one of the following: (a) stroke (onset 2-24 months), (b) incomplete spinal cord injury (neurological level T12 or below, ASIA Impairment Scale C or D), or (c) orthopedic surgery (e.g., knee\u002Fhip replacement) with persistent gait impairment more than 3 months post-surgery\n* Age greater than 18 years and up to 60 years\n* Medically stable and able to provide informed consent\n* Able to meet device anthropometric criteria for use of the ZEPU-AI5 system\n\nExclusion Criteria:\n\n* Complete spinal cord injury with inability to bear any weight\n* Severe cognitive impairment (Mini-Mental State Examination score less than 24) preventing safe participation\n* Severe spasticity of the lower limbs (Modified Ashworth Scale greater than 3)\n* Unstable fractures, severe hip\u002Fknee contractures (greater than 30 degrees fixed flexion), or severe osteoarthritis requiring imminent surgery\n* Uncontrolled cardiac arrhythmia, pacemaker incompatibility, or any implanted electronic device incompatible with the robot's sensors\n* Pregnancy",{"count":157,"type":21},[24],"The goal of this clinical trial is to learn if robot-assisted lower-limb strength and gait training can improve safety, feasibility, and functional recovery in adults aged 18-60 years with lower-limb motor dysfunction due to stroke, incomplete spinal cord injury, or persistent gait impairment following orthopedic surgery. The main questions it aims to answer are:\n\nIs robot-assisted training using the ZEPU-AI5 device safe and well-tolerated, with an acceptable rate of device-related adverse events? Does adding ZEPU-AI5-assisted training to standard-of-care rehabilitation improve functional outcomes (such as walking distance, muscle strength, balance, and mobility) compared to standard-of-care rehabilitation alone?\n\nResearchers will compare an intervention group receiving standard-of-care rehabilitation combined with ZEPU-AI5-assisted training to a control group receiving standard-of-care rehabilitation alone, to see if the addition of robotic training leads to greater improvements in safety, functional recovery, and quality of life.\n\nParticipants will:\n\nUndergo a baseline assessment before starting the study Receive either robot-assisted training plus standard-of-care rehabilitation, or standard-of-care rehabilitation alone, three times per week for 12 weeks Complete follow-up assessments every two weeks to evaluate safety, functional outcomes, and durability of any benefits",[161,388,411],"Gait Impairment Following Orthopedic Surgery",[167,168,413],"Muscle Strength",{"date":395,"type":32},{"date":397,"type":21},{"date":201,"type":21},{"name":37,"class":38},{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":4,"eligibilityCriteria":424,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":155,"enrollmentInfo":425,"targetDuration":4,"studyType":22,"phases":427,"briefSummary":428,"conditions":429,"keywords":431,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":433,"startDateStruct":434,"completionDateStruct":435,"leadSponsor":436,"locationsCount":39},"100649539","zepu-ai1-gait-robot-training-study-zepuai1rct-100649539","NCT07735676","ZEPU-AI1 Gait Robot Training Study (ZEPUAI1RCT)","Feasibility, Safety and Efficacy of ZEPU AI1 Gait Training and Evaluation System Robot in Patients With Lower Limb Motor Weakness","Inclusion Criteria:\n\n* Lower-limb motor dysfunction from one of the following: (a) stroke (onset 2-24 months), (b) incomplete spinal-cord injury (neurological level T12 and below, ASIA C or D), (c) orthopedic surgery (e.g., knee\u002Fhip replacement) with persistent gait impairment \\>3 months post-surgery\n* Age \\>18 and ≤60 years\n* Able to provide informed consent and understand instructions\n* Weight ≤100 kg and height within device adjustable range (per manufacturer specification)\n* Medically stable and cleared by physician for exoskeleton use (no active infection, uncontrolled cardiac\u002Frespiratory disease, severe osteoporosis, uncontrolled epilepsy, or untreated DVT)\n\nExclusion Criteria:\n\n* Complete spinal cord injury with inability to bear any weight\n* Severe cognitive impairment (e.g., MMSE \\\u003C24) preventing safe participation\n* Severe spasticity (Modified Ashworth Scale \\>3) in lower limbs\n* Unstable fractures, severe hip\u002Fknee contractures (\\>30° fixed flexion), or severe osteoarthritis requiring imminent surgery\n* Uncontrolled cardiac arrhythmia, pacemaker incompatibility, or implanted electronic device incompatible with robot sensors\n* Pregnancy",{"count":426,"type":21},32,[24],"Walking problems caused by stroke, spinal cord injury, or orthopedic surgery are common and can seriously limit a person's independence. Robotic-assisted gait training devices, which use a computer-controlled system to help patients practice standing and walking, have shown promise in improving strength, balance, and walking ability in other countries. However, this type of technology has not yet been carefully studied in Bangladesh.\n\nThis study will test a robotic gait training and evaluation device called ZEPU-AI1 in adults aged 19 to 60 years who have difficulty walking due to stroke, incomplete spinal cord injury, or gait problems following surgery. The main goals are to find out whether using this robotic device alongside standard physical therapy is feasible (practical to carry out) and safe, and to explore whether it helps improve walking speed, balance, muscle strength, and daily function compared with standard physical therapy alone.\n\nThirty-two participants will take part. Half will receive robot-assisted gait training three times a week for 12 weeks in addition to usual rehabilitation therapy, while the other half will receive usual rehabilitation therapy alone. Participants will be assessed regularly using standard walking, balance, and strength tests over the 12-week period.\n\nThe results of this study will help doctors and researchers understand whether this robotic technology can be safely and effectively introduced into rehabilitation care in Bangladesh.",[161,430,162],"Spinal Cord Injuries (SCI)",[432,167,168],"Gait Training",{"date":395,"type":32},{"date":397,"type":21},{"date":201,"type":21},{"name":37,"class":38},{"id":438,"slug":439,"hasResults":12,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":443,"eligibilityCriteria":444,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":445,"enrollmentInfo":446,"targetDuration":4,"studyType":22,"phases":447,"briefSummary":448,"conditions":449,"keywords":451,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":39},"100647089","zepu-ai3-lower-limb-feedback-robot-training-study-100647089","NCT07705906","ZEPU-AI3 Lower Limb Feedback Robot Training Study","Safety, Efficacy and Feasibility of ZEPU-AI3 Lower Limb Feedback Training and Evaluation Robot","ZEPUAI3RCT","Inclusion Criteria:\n\n* • Lower-limb motor dysfunction from one of the following: (a) stroke (onset 2-24 months), (b) incomplete spinal-cord injury (neurological level T12 and below, ASIA C or D), (c) orthopedic surgery (e.g., knee\u002Fhip replacement) with persistent gait impairment \\> 3month post-surgery. Stroke onset between 2-24 months ensures inclusion of individuals in the subacute to chronic phase, where gait recovery is still achievable and measurable. Incomplete SCI targets individuals with partial motor preservation, who are capable of engaging in active gait training with robotic assistance.\n\n  * Age \\>18 and ≤ 60 years. This age limit is chosen because individuals with this age range generally have better cardiopulmonary reserve and musculoskeletal tolerance, allowing safer participation in intensive robotic-assisted training with reduced risk of adverse events. Excluding younger patients minimizes heterogeneity related to growth, neurodevelopmental factors and congenital disorders, which may influence gait mechanics and response to robotic therapy. Excluding older adults (\\>60 years) helps reduce confounding from age-related degenerative changes that may affect gait outcomes and safety.\n  * Able to provide informed consent and understand instructions which ensures participants can actively engage in therapy, follow safety instructions and report adverse events.\n  * Weight ≤ 100 kg (as per device spec) and height within device adjustable range (manufacturer spec). Exceeding weight or height limits may compromise mechanical support, safety, and accurate gait training.\n  * Medically stable and cleared by physician for exoskeleton use (no active infection, uncontrolled cardiac\u002Frespiratory disease, severe osteoporosis, uncontrolled epilepsy, untreated DVT) through pre-screening with necessary investigations.\n\nExclusion Criteria:\n\n* • Complete spinal cord injury with inability to bear any weight as it requires the patient to actively support some body weight or participate in stepping movements.\n\n  * Severe cognitive impairment (e.g., MMSE \\\u003C 24) preventing safe participation.\n  * Severe spasticity (Modified Ashworth Scale \\> 3) in lower limbs. High muscle tone or rigidity increases risk of joint strain, skin injury and falls during robotic-assisted training.\n  * Unstable fractures, severe hip\u002Fknee contractures (\\> 30° fixed flexion), severe osteoarthritis requiring imminent surgery. They can pose high risk for injury during weight-bearing or gait cycles.\n  * Uncontrolled cardiac arrhythmia, pacemaker incompatibility or implanted electronic device incompatible with robot sensors. Individuals with these conditions may face elevated risk of adverse cardiac events or device malfunction.\n  * Pregnancy as safety data for robotic exoskeleton use in pregnant individuals are lacking.","70 Years",{"count":426,"type":21},[24],"Lower limb motor dysfunction resulting from stroke, spinal cord injury, or other neurological disorders substantially limits mobility, independence, and quality of life. Robotic rehabilitation has emerged as a promising approach to provide intensive, repetitive, task-oriented training. The ZEPU-AI3 Lower Limb Feedback Training and Evaluation Robot is designed to deliver interactive lower limb training while providing real-time performance feedback. This pilot randomized controlled trial aims to evaluate the safety, efficacy, and feasibility of ZEPU-AI3-assisted rehabilitation combined with conventional rehabilitation compared with conventional rehabilitation alone in patients with lower limb motor dysfunction. The primary outcomes include safety, feasibility, and changes in lower limb motor function, gait performance, and functional mobility. The findings will provide preliminary evidence to support future large-scale clinical trials and the implementation of robotic rehabilitation in clinical practice.",[161,187,450],"Gait Disorders",[167,168,452],"Feedback Training","2026-07-26",{"date":455,"type":32},"2026-07-28",{"date":457,"type":21},"2026-07-15",{"date":459,"type":21},"2026-11-15",{"name":37,"class":38},{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":22,"phases":469,"briefSummary":470,"conditions":471,"keywords":473,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":482,"leadSponsor":484,"locationsCount":39},"100646008","rationale-of-subcutaneous-levofloxacin-infiltration-as-an-adjunct-for-surgical-site-infection-prevention-in-emergency-laparotomy-100646008","NCT07696819","Rationale of Subcutaneous Levofloxacin Infiltration as an Adjunct for Surgical Site Infection Prevention in Emergency Laparotomy","Inclusion Criteria:\n\n* Patients aged 18 years and above\n* Patients undergoing emergency laparotomy for contaminated surgical pathology\n* Patients undergoing emergency laparotomy for dirty\u002Finfected surgical pathology\n\nExclusion Criteria:\n\n* Patients with known hypersensitivity to levofloxacin or other fluoroquinolones\n* Pregnant women or lactating mothers\n* Patients with pre-existing severe renal impairment\n* Patients with pre-existing skin infection at the incision site\n* Patients requiring re-laparotomy within 48 hours",{"count":468,"type":21},90,[24],"Surgical site infection (SSI) remains a major cause of postoperative morbidity following emergency laparotomy, particularly in contaminated and dirty\u002Finfected abdominal conditions. Systemic antibiotic prophylaxis alone often fails to achieve adequate local tissue concentrations at the incision site due to impaired perfusion, contributing to persistently high SSI rates in this population.\n\nThis trial evaluates subcutaneous infiltration of levofloxacin, a broad-spectrum fluoroquinolone with favorable tissue penetration, administered along the wound edges immediately prior to skin closure, as an adjunct to standard surgical and antibiotic management.\n\nThis study is investigator-initiated and will be conducted as a single-center trial within the Department of Surgery, Sylhet MAG Osmani Medical College Hospital.",[472],"Surgical Site Infection (SSI)",[474,475,476,477],"Surgical Site Infection","Emergency Laparotomy","Subcutaneous Infiltration","Levofloxacin","2026-07-10",{"date":480,"type":32},"2026-07-13",{"date":308,"type":21},{"date":483,"type":21},"2026-10-31",{"name":485,"class":38},"Sylhet M.A.G.Osmani Medical College",{"id":487,"slug":488,"hasResults":12,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":236,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":493,"targetDuration":4,"studyType":297,"phases":4,"briefSummary":495,"conditions":496,"keywords":4,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":503,"locationsCount":39},"100646231","prevalence-of-functional-dyspepsia-in-a-rural-community-of-bangladesh--a-cross-sectional-study-100646231","NCT07694778","Prevalence of Functional Dyspepsia in a Rural Community of Bangladesh : A Cross Sectional Study","Prevalence of Functional Dyspepsia in Rural Community of Bangladesh: A Cross Sectional Study","Inclusion Criteria:\n\n* Age 18 years or above\n* Resident of the selected community\n\nExclusion Criteria:\n\n* Known diagnosis of organic GI diseases.(e.g., Peptic ulcer disease, Inflammatory Bowel Disease, celiac disease, Malignancy, Intestinal Tuberculosis)\n* Severe cognitive impairment, or critical illness\n* Individuals with a history of major abdominal surgery\n* Pregnant women",{"count":494,"type":21},730,"Functional dyspepsia (FD) is a common gastrointestinal disorder with an important impact on quality of life. There is a paucity of updated data on the prevalence of FD in rural areas of Bangladesh. The present study will be carried out to find the prevalence of FD in a community in rural Bangladesh. It also assesses potential risk factors. Eligible participants will first be evaluated for symptoms by a clinical interview using the standardized Rome IV functional dyspepsia questionnaire. Those who meet Rome IV criteria will then have an upper gastrointestinal endoscopy to exclude underlying organic diseases to establish a definitive diagnosis. Eventually patients with normal endoscopic findings will be diagnosed as having functional dyspepsia. This allows the accurate calculation of disease prevalence. Researchers will gather demographic information, lifestyle habits, and dietary patterns. The results will give important baseline data on rural FD burdens. Such data can inform community health care interventions.",[497],"Functional Dyspepsia","2026-07-05",{"date":478,"type":32},{"date":501,"type":32},"2026-01-10",{"date":174,"type":21},{"name":37,"class":38},{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":236,"sex":17,"minAge":129,"maxAge":4,"enrollmentInfo":511,"targetDuration":4,"studyType":22,"phases":513,"briefSummary":514,"conditions":515,"keywords":518,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":39},"100646921","cholera-control-by-case-area-targeted-interventions-catis-100646921","NCT07685574","Cholera Control by Case-area Targeted Interventions (CATIs)","Case-area Targeted Interventions (CATIs) Among Household Contacts and Neighbouring Households After Defining Cholera Hotspot Areas in Bangladesh: The Effectiveness of OCV and Potential Impact on Cholera Control","Index case eligibility\n\nInclusion Criteria:\n\n1. Some to severe dehydrated diarrheal patient\n2. Provide signed informed consent form\n\nExclusion criteria:\n\n1\\. Resident in a ward already covered by OCV since 2015\n\nVaccination Eligibility\n\nInclusion Criteria:\n\n1. Aged ≥1 year and non-pregnant\n2. Meeting the definition of IHC and NHC\n3. Provide signed informed consent form\n\nExclusion criteria:\n\n1. History of taking OCV\n2. Currently suffering from diarrhea\n3. \\\u003C 1 year of age\n4. Pregnant women (verbally confirmed)\n5. Index case",{"count":512,"type":21},68400,[24],"To evaluate the effectiveness of the CATI approach among household contacts in the reduction of cumulative incidence of cholera and explore the genome analysis and immune response of V. cholerae antigen from different hotspots in Dhaka city, cholera cases will be enrolled by rapid diagnostic test (RDT) from the diarrhoeal patients coming to icddr,b Dhaka hospital. Hotspots will be defined as the households (HHs) surrounding the RDT-positive cholera case (around 20-40m radius). The 'Case area targeted interventions' (CATI) will be given by administrating Oral Cholera Vaccine (OCV) with either one dose or two doses of OCV 1 month apart among household contacts (≥1-year age and non-pregnant women) and contacts of the contacts residing in the adjacent HHs. The passive surveillance for cholera will be followed using the icddr,b hospital, and other health facilities. Data on each individual's states of the clusters (e.g., susceptible, exposed, infectious, or recovered) will be tracked throughout the 3 years study follow-up.",[516,517],"Cholera","Methodology Study",[516,519,520,59],"CATI","Cholera Vaccine","2026-07-01",{"date":523,"type":32},"2026-07-06",{"date":525,"type":32},"2024-09-05",{"date":527,"type":21},"2029-12-31",{"name":375,"class":38},{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":533,"acronym":4,"eligibilityCriteria":534,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":535,"targetDuration":4,"studyType":22,"phases":536,"briefSummary":537,"conditions":538,"keywords":541,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":39},"100646822","efficacy-and-safety-of-finerenone-compared-to-spironolactone-in-treatment-of-primary-aldosteronism-100646822","NCT07688928","Efficacy and Safety of Finerenone Compared to Spironolactone in Treatment of Primary Aldosteronism","Inclusion Criteria:\n\n1. Age \\>18 years.\n2. History of hypertension (blood pressure \\>140\u002F90 mm Hg), both newly detected and already established patients.\n3. Diagnosed case of primary aldosteronism (PA) based on a screening test (increased aldosterone renin ration (ARR) \\>70pmol\u002FL) and confirmed by saline suppression test (post-saline PAC \\>170pmol\u002FL, where PAC measured by immunoassay).\n4. Serum potassium ≥2.5 mmol\u002FL.\n\nExclusion Criteria:\n\n1. Uncontrolled hypertension (\\>180\u002F120 mm Hg).\n2. Lateralized PA patients (aldosterone producing adenoma or unilateral hyperplasia) who want to undergo adrenalectomy or having aldosterone producing carcinoma.\n3. Participants already with mineralocorticoid receptor antagonist treatment.\n4. Patients receiving medications confounding PAC or PRC (glucocorticoids, sodium glucose co-transporter 2 inhibitors (SGLT-2i) or systemic therapy with potent cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors (e.g. itraconazole, clarithromycin, rifampicin, carbamazepine, phenytoin, phenobarbital, efavirenz) that cannot be discontinued 14 days prior to randomization or for the duration of treatment period.\n5. Abnormal renal function test: eGFR \\\u003C60 ml\u002Fmin-1.73m2.\n6. Serum potassium level \\>5 mmol\u002FL.\n7. Recent cardiovascular events like acute myocardial ischemia, heart failure with hospitalization, stroke or transient ischemic attack ≤3 months before the screening visit.\n8. Uncontrolled DM (HbA1C \\>12%)\n9. Hepatic insufficiency (Child-Pugh C)\n10. Addison's disease\n11. Pregnant and lactating women. Women with child bearing potential must agree to use adequate contraception during and until 2 month of the end of study period.\n12. Patient with other form of secondary HTN (e.g. renovascular HTN, Cushing syndrome, pheochromocytoma, coarctation of aorta etc.)\n13. Known hypersensitivity to the study drugs.\n14. Patients unwilling to participate in this study",{"count":48,"type":21},[24],"The goal of this study is to compare the efficacy and safety of finerenone versus spironolactone in the treatment of hypertension due to primary aldosteronism.\n\nIt will be a randomized, double-blind, active-controlled, parallel-group clinical trial conducted at the Endocrine Hypertension Clinic, Department of Endocrinology, BSMMU. A total of 104 adult patients with confirmed primary aldosteronism will be enrolled and randomized equally to receive either finerenone (10-40 mg\u002Fday) or spironolactone (25-100mg\u002Fday) for 48 weeks. Study drugs will be titrated to achieve target blood pressure (\\\u003C140\u002F90mmHg) and unsuppressed plasma renin concentration (\\>15 mU\u002FL). The primary efficacy outcome will be the time and daily dose required to attain this composite endpoint. Secondary outcomes include changes in clinic and ambulatory blood pressure, plasma aldosterone and renin levels, renal function (eGFR), urinary albumin excretion, left ventricular mass index, and quality of life. Safety outcomes will include adverse events, particularly hyperkalaemia and deterioration of renal function.",[539,540],"Primary Aldosteronism","Endocrine Hypertension",[539,542,543],"Finerenone","Spironolactone","2026-06-30",{"date":546,"type":32},"2026-07-07",{"date":548,"type":32},"2026-04-15",{"date":550,"type":21},"2027-09",{"name":37,"class":38},{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":558,"eligibilityCriteria":559,"healthyVolunteers":236,"sex":17,"minAge":4,"maxAge":560,"enrollmentInfo":561,"targetDuration":4,"studyType":22,"phases":563,"briefSummary":564,"conditions":565,"keywords":570,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":39},"100637574","perinatal-mortality-outcomes-through-household-infection-pathways-100637574","NCT07620613","Perinatal Mortality Outcomes Through Household Infection Pathways","Effect of Cement Floors on Perinatal and Neonatal Mortality in Bangladesh: a Randomized Trial in Rural Bangladesh","POTH","Inclusion Criteria:\n\n* Prior enrollment in the CRADLE trial (NCT05372068), in either arm, and currently residing in the original CRADLE-enrolled household\n* Residence in Sirajganj or Tangail districts in Bangladesh\n* No major non-compliance (e.g., no removal of concrete floor in intervention arm or installation of concrete floor in control arm)\n* No plan to relocate within the study follow-up period\n* Incident pregnancy occurring after CRADLE trial enrollment, confirmed after 26 weeks gestation","6 Years",{"count":562,"type":21},196,[24],"The goal of this trial is to learn if replacing household soil floors with concrete floors can prevent deaths of infants around the time of birth, including stillbirths and deaths in the first month of life in rural Bangladesh. The primary question the study aims to answer is: Does residing in a home with a concrete vs. soil floor reduce the perinatal and neonatal morality in index children and their younger siblings up to 6 years post-installation of concrete floors?\n\nResearchers will compare participants in households with concrete floors (intervention) vs. soil floors (comparison group) to see if concrete floors reduce the rate of perinatal death and child death up the 6 years post-intervention.\n\nThis study will extend an ongoing NIH-funded randomized trial in which households with soil floors where a pregnant woman resided were randomly chosen to receive a concrete floor intervention or to retain their existing soil floor. This study will track pregnancies, births, and deaths among infants born to pregnant mothers in the original study to measure effects of household concrete flooring up to 6 years after the concrete floors were installed.",[566,567,568,569],"Stillbirth and Neonatal Mortality","Perinatal Mortality","Infant Mortality","Child Mortality",[571,572,573,574],"concrete floor","soil floor","dirt floor","housing intervention","2026-06-27",{"date":521,"type":32},{"date":578,"type":21},"2026-06-01",{"date":580,"type":21},"2029-05-01",{"name":582,"class":38},"Stanford University",{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":589,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":591,"enrollmentInfo":592,"targetDuration":4,"studyType":22,"phases":594,"briefSummary":595,"conditions":596,"keywords":598,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":603,"lastUpdatePostDateStruct":604,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":610,"locationsCount":613},"100581807","phase-3-caffeine-for-hypoxic-ischemic-encephalopathy-100581807","NCT06855108","Caffeine for Hypoxic Ischemic Encephalopathy","Caffeine for Hypoxic Ischemic Encephalopathy (CHIME Trial)","CHIME","Participant Inclusion Criteria:\n\nInfants who meet all the following criteria are eligible for enrollment as study participants:\n\n1. Liveborn infants ≥36 weeks\n2. Birth weight ≥1800 grams\n3. Meets physiologic criteria for moderate to severe HIE, defined as meeting either of the following two criteria:\n\n   1. Criterion #1: Severe acidosis, defined as an umbilical cord sample or neonatal serum sample within one hour after birth demonstrating any of following criteria:\n\n      * pH \\\u003C7.0; or\n      * Base Deficit ≥16 mmol\u002FL; or\n      * Lactate \\>8 mmol\u002FL.\n   2. Criterion #2: Participant must meet all of the following three criteria:\n\n   i. Moderate acidosis, defined as an umbilical cord sample or neonatal serum sample within one hour after birth demonstrating any of following criteria:\n   * POC pH 7.0-7.15; or\n   * Base Deficit 10.0-15.9 mmol\u002FL; or\n   * Lactate 6-8 mmol\u002FL.\n\n   ii. Evidence of an acute perinatal event (i.e., placental abruption, intrapartum hemorrhage, cord prolapse, severe fetal heart rate abnormality, uterine rupture).\n\n   iii. Any of the following criteria:\n   * 10-minute Apgar \\\u003C5; or\n   * Need for assisted ventilation initiated at birth and continued for ≥10 minutes\n4. Meets neurologic criteria for moderate to severe HIE, defined as a physical exam conducted between one and six hours after birth that meets either of the following criteria:\n\n   1. Moderate to severe encephalopathy in at least three out of six modified Sarnat categories (level of consciousness, spontaneous activity, muscle tone, posture, primitive reflexes, autonomic function); or\n   2. A clinical diagnosis of seizure in the first six hours after birth.\n\nParticipant Exclusion Criteria:\n\nInfants who meet any of the following criteria are not eligible for enrollment as study participants:\n\n1. Home births\n2. Infants who cannot be enrolled, randomized and receive study medication within 6 hours post-delivery\n3. Infants with a recognized major congenital anomaly or genetic syndrome that would affect their neurodevelopment.\n4. Infants for whom medical care will not be provided based on the severity of their condition or any other condition that would preclude participation per clinical judgement.\n5. Infant has received therapeutic hypothermia or there is a clinical plan to initiate active or passive hypothermia for the infant.\n6. Infants who will be unavailable to complete follow-up visits.\n7. Infants who have received caffeine after delivery.\n8. Infants whom the health care team deem ineligible for the study based on likelihood to receive caffeine outside of the study protocol.\n9. Enrollment in another trial that will impact participation in this trial.","6 Hours",{"count":593,"type":21},830,[268],"CHIME is a randomized, parallel-arm, double-blind, placebo-controlled trial focused on infants with hypoxic ischemic encephalopathy (HIE). The trial will recruit neonates who are diagnosed with HIE within six hours after birth based on physiologic criteria (acidosis noted on an umbilical cord or early \\[\\\u003C1 hour\\] postnatal blood sample) and neurologic criteria (modified Sarnat exam consistent with encephalopathy). Following informed consent, and by six hours after birth, neonates with HIE will be randomized to one of two treatment arms and subsequently receive one 20 mg\u002Fkg dose of oral caffeine followed by two additional 10 mg\u002Fkg doses at 24-hour intervals or placebo of the same regimen (three total doses).\n\nThe goal of this clinical trial is to compare the incidence of all-cause mortality OR moderate to severe neurodevelopmental impairment (NDI) at 18-22 months between neonates with HIE who are randomized to oral caffeine or placebo. Our hypothesis is that neonates with HIE who receive oral caffeine will have 10% lower incidence of all-cause mortality or moderate to severe NDI at 18-22 months compared to placebo.",[597],"Hypoxic Ischemic Encephalopathy (HIE)",[599,600,601,602],"Caffeine","Hypoxic Ischemic Encephalopathy","HIE","AKI","2026-06-19",{"date":605,"type":32},"2026-06-24",{"date":607,"type":32},"2026-04-08",{"date":609,"type":21},"2030-07",{"name":611,"class":612},"NICHD Global Network for Women's and Children's Health","NETWORK",7,{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":619,"acronym":4,"eligibilityCriteria":620,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":238,"enrollmentInfo":621,"targetDuration":4,"studyType":22,"phases":623,"briefSummary":624,"conditions":625,"keywords":627,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":632,"lastUpdatePostDateStruct":633,"startDateStruct":635,"completionDateStruct":636,"leadSponsor":638,"locationsCount":39},"100641611","phase-4-comparison-of-propranolol-flunarizine-and-their-combination-in-preventing-migraine-in-adults-in-a-tertiary-care-hospital-in-bangladesh-100641611","NCT07655700","Comparison of Propranolol, Flunarizine and Their Combination in Preventing Migraine in Adults in a Tertiary Care Hospital in Bangladesh","Comparative Efficacy of Propranolol, Flunarizine, and Their Combination in Migraine Prophylaxis: An Open-label Parallel-arm Randomized Controlled Trial","Inclusion Criteria:\n\n1. Participants aged 18 to 55 years.\n2. Diagnosis of episodic migraine, defined according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria.\n3. Participants experiencing 4 or more migraine attacks per month.\n4. Willingness to provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Comorbidities:\n\n   * Presence of other primary headache disorders, chronic migraine, hemiplegic migraine, basilar migraine or any secondary headache disorder.\n   * Known serious underlying systemic diseases including Cardiac disease (Heart failure, Heart Block, Arrhythmia), Renal dysfunction, Liver dysfunction, Pulmonary disease (Asthma, COPD), Peripheral vascular disease, Extrapyramidal disease (Parkinson disease, Chorea, Dystonia).\n   * Pregnancy or breastfeeding.\n   * Psychiatric illness (Depression, Psychosis, Obsessive compulsive disorder).\n2. Medications:\n\n   * Received migraine prophylactic medication within 60 days prior to screening.\n   * Use of specific contraindicated medications, including beta-blockers or calcium channel blockers, except as part of the study treatments.\n3. Non-compliance:\n\n   * Inability or unwillingness to comply with study protocols, including maintaining a headache diary or attending follow-up visits.\n4. History of Allergies:\n\n   * Known hypersensitivity to propranolol, flunarizine\n5. Substance Use:\n\n   * Current substance abuse",{"count":622,"type":21},177,[325],"Migraine is a common and disabling neurological condition that affects quality of life, work productivity, and daily functioning. In Bangladesh, migraine is a major health problem, yet access to effective and affordable preventive treatments remains limited. Preventive (prophylactic) treatment is recommended for people who experience frequent migraine attacks in order to reduce the number, severity, and duration of headaches.\n\nPropranolol and flunarizine are two commonly used and relatively inexpensive medications for migraine prevention. Both drugs have been shown to reduce migraine frequency when used alone. However, some patients do not respond adequately to a single medication. Using a combination of drugs that work through different mechanisms may improve treatment effectiveness without significantly increasing side effects. There is limited local evidence comparing propranolol, flunarizine, and their combination in migraine prevention, particularly in the Bangladeshi population.\n\nThis study is designed to compare the effectiveness and safety of propranolol alone, flunarizine alone, and a combination of propranolol and flunarizine in preventing episodic migraine in adults. The main hypothesis is that at least one of these treatment strategies, particularly combination therapy, may be more effective than the others in reducing migraine burden.\n\nThis is an open-label, parallel-arm, randomized controlled trial conducted at Chittagong Medical College Hospital, Bangladesh. A total of 177 adult patients aged 18 to 55 years who are diagnosed with episodic migraine and experience four or more migraine attacks per month will be enrolled. Participants will be randomly assigned to one of three treatment groups: propranolol, flunarizine, or a combination of both medications. Treatment will be given for 12 weeks, with dose adjustments during the first week and follow-up visits at 6 and 12 weeks.\n\nThe primary outcome of the study is the reduction in the number of monthly migraine days. Secondary outcomes include the proportion of patients achieving at least a 50% reduction in migraine days, changes in headache severity and duration, improvement in migraine-related disability (measured by the Migraine Disability Assessment Score), patient-reported treatment satisfaction, and the frequency of side effects.\n\nThe results of this study are expected to provide important local evidence to guide clinicians in selecting effective and affordable migraine preventive treatments and to clarify whether combination therapy offers additional benefits over single-drug therapy in routine clinical practice.",[626],"Migraine Prophylaxis",[626,628,629,630,631],"Randomized Controlled Trial","Combination Therapy","Propranolol","Flunarizine","2026-06-17",{"date":634,"type":32},"2026-06-22",{"date":521,"type":21},{"date":637,"type":21},"2027-04-30",{"name":639,"class":38},"Chittagong Medical College",{"id":641,"slug":642,"hasResults":12,"nctId":643,"briefTitle":644,"officialTitle":645,"acronym":4,"eligibilityCriteria":646,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":647,"targetDuration":4,"studyType":22,"phases":649,"briefSummary":650,"conditions":651,"keywords":655,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":660,"lastUpdatePostDateStruct":661,"startDateStruct":662,"completionDateStruct":664,"leadSponsor":666,"locationsCount":39},"100642090","coeliac-plexus-vs-splanchnic-nerve-neurolysis-for-upper-abdominal-cancer-pain-100642090","NCT07653906","Coeliac Plexus vs Splanchnic Nerve Neurolysis for Upper Abdominal Cancer Pain","Effect of Coeliac Plexus Versus Splanchnic Nerve Neurolysis in Pain Management With Upper Abdominal Malignancies","Inclusion Criteria:\n\n* Adult patient\n* Both genders\n* Diagnosed case of upper abdominal malignancy (pancreatic, gastric, hepatic, or biliary origin)\n* Experiencing moderate to severe pain (≥5 on a 10 point visual analog scale)\n* Patients who are conscious and can communicate\n* No Contraindication for nerve block (e.g., coagulopathy, anticoagulant drugs)\n\nExclusion Criteria:\n\n* Previous coeliac plexus block, splanchnic nerve block, or major abdominal nerve ablation\n* Severe spinal deformities or anatomical distortion at the coeliac plexus or splanchnic nerve site\n* Local or systemic infection at or near the block site\n* Known allergy to local anesthetics or neurolytic agents\n* Pregnancy\n* Lactating mother\n* Cognitive impairment or psychiatric illness",{"count":648,"type":21},44,[24],"The goal of this clinical trial is to determine whether Neurolytic Splanchnic Nerve Block (NSNB) reduces pain in adults with upper abdominal malignancies. It will also evaluate the safety of Neurolytic Splanchnic Nerve Block (NSNB). The main questions it aims to answer are:\n\nDoes NSNB reduce pain intensity compared to Neurolytic Coeliac Plexus Block (NCPB), as measured by the Visual Analog Scale (VAS)? What adverse effects do participants experience when receiving Neurolytic Splanchnic Nerve Block (NSNB)?\n\nInvestigators will compare Neurolytic Splanchnic Nerve Block (NSNB) with Neurolytic Coeliac Plexus Block (NCPB) to determine which intervention provides more effective and safer pain relief.\n\nParticipants will:\n\n* receive either NSNB or NCPB under fluoroscopic guidance\n* be monitored immediately and for 2 hours after the procedure for any complications Have their pain intensity recorded immediately after the procedure, and at 7 days, 1 month, and 3 months\n* be evaluated for quality-of-life using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 3 (EORTC QLQ-C30) at 1 month and 3 months.\n* have their opioid consumption tracked throughout the study.",[652,653,654],"Abdominal Neoplasms","Pain Management","Neurolytic Techniques",[656,657,658,659],"Upper abdominal cancer","Splanchnic nerve block","Coeliac plexus block","Analgesic efficacy","2026-06-12",{"date":632,"type":32},{"date":663,"type":32},"2026-05-01",{"date":665,"type":21},"2027-01-31",{"name":37,"class":38},""]